When is the next results date for Sun Pharma.Inds.?

No Upcoming Board Meetings

What is the bonus history of the Sun Pharma.Inds.?

Sun Pharmaceutical Industries Ltd issued a 1:1 bonus on July 29, 2013, with a record date of July 30, 2013, allowing shareholders to double their holdings.

Sun Pharmaceutical Industries Ltd has a bonus history that includes a 1:1 bonus issue announced on July 29, 2013. The record date for this bonus was July 30, 2013. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about Sun Pharma or need further details, feel free to ask!

Has Sun Pharma.Inds. declared dividend?

Yes, Sun Pharmaceutical Industries Ltd has declared a 1050% dividend, amounting to ₹10.5 per share, with an ex-date of February 6, 2025. The company has shown strong total returns over various periods, particularly a 250.91% total return over the last 5 years.

Sun Pharmaceutical Industries Ltd has declared a 1050% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1050%<BR>- Amount per share: 10.5<BR>- Ex-date: Feb-06-2025<BR><BR>Dividend Yield: 0.92%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -7.05%, the dividend return was 0.58%, resulting in a total return of -6.47%.<BR><BR>For the 1-year period, the price return was 13.9%, the dividend return was 1.03%, leading to a total return of 14.93%.<BR><BR>Over the 2-year period, the price return was 65.52%, the dividend return was 2.80%, culminating in a total return of 68.32%.<BR><BR>In the 3-year period, the price return was 94.83%, the dividend return was 4.76%, which resulted in a total return of 99.59%.<BR><BR>For the 4-year period, the price return was 148.84%, the dividend return was 7.02%, yielding a total return of 155.86%.<BR><BR>In the 5-year period, the price return was 239.5%, the dividend return was 11.41%, resulting in a total return of 250.91%.<BR><BR>Overall, Sun Pharma's declaration of a significant dividend reflects a strong commitment to returning value to shareholders, and the total returns over various periods indicate robust growth, particularly over the longer term.

Is Sun Pharma.Inds. overvalued or undervalued?

As of May 23, 2025, Sun Pharmaceutical Industries Ltd. is considered overvalued with a PE ratio of 35.25 and a valuation grade of expensive, despite strong fundamentals, as it has underperformed the Sensex with a year-to-date return of -10.51%.

As of 23 May 2025, the valuation grade for Sun Pharmaceutical Industries Ltd. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still reflecting a high valuation. The company is currently considered overvalued, with a PE ratio of 35.25, a Price to Book Value of 5.58, and an EV to EBITDA of 24.91. <BR><BR>In comparison to peers, Sun Pharma's PE ratio is higher than that of its competitor, which has a PE of approximately 30. This suggests that Sun Pharma is priced at a premium relative to its industry peers. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -10.51% compared to the Sensex's 5.58%. Overall, while there are strong fundamentals such as a ROCE of 25.60% and a ROE of 15.83%, the current valuation metrics indicate that Sun Pharma is overvalued in the market.

Who are the peers of the Sun Pharma.Inds.?

Sun Pharma.Inds. peers include Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, and Glenmark Pharma. Divi's Lab. leads in 1-year returns at 49.58%, while Aurobindo Pharma has the lowest at -16.00%; Sun Pharma.Inds. has a 1-year return of 7.67%.

Peers: The peers of Sun Pharma.Inds. are Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and the rest. Good growth is noted at Sun Pharma.Inds., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and the rest, while Below Average growth is found at Divi's Lab., Torrent Pharma, Aurobindo Pharma, and the rest. Excellent capital structure is seen at Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, Aurobindo Pharma, and the rest, while Good capital structure is noted at Torrent Pharma and Lupin, and Average capital structure is found at Lupin and Glenmark Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 49.58%, while Aurobindo Pharma has the lowest at -16.00%. Sun Pharma.Inds. has a 1-year return of 7.67%, which is higher than Aurobindo Pharma but lower than Divi's Lab. Additionally, Zydus Lifesci., Dr Reddy's Labs, and Lupin have negative six-month returns.

Who are in the management team of Sun Pharma.Inds.?

As of March 2022, the management team of Sun Pharma.Inds. includes Dilip S Shanghvi (Managing Director), Sudhir V Valia, Sailesh T Desai, Gautam Doshi, Pawan Goenka, Rama Bijapurkar, Anoop Deshpande (Company Secretary), Sanjay K Asher, Rolf Hoffmann, and Aalok Shanghvi (Whole-time Director), overseeing the company's strategic direction.

As of March 2022, the management team of Sun Pharma.Inds. includes the following individuals:<BR><BR>1. **Dilip S Shanghvi** - Managing Director<BR>2. **Sudhir V Valia** - Non-Executive & Non-Independent Director<BR>3. **Sailesh T Desai** - Whole-time Director<BR>4. **Gautam Doshi** - Non-Executive & Independent Director<BR>5. **Pawan Goenka** - Lead Independent Director<BR>6. **Rama Bijapurkar** - Independent Director<BR>7. **Anoop Deshpande** - Company Secretary & Compliance Officer<BR>8. **Sanjay K Asher** - Independent Director<BR>9. **Rolf Hoffmann** - Independent Director<BR>10. **Aalok Shanghvi** - Whole-time Director<BR><BR>This team is responsible for the strategic direction and management of the company.

What does Sun Pharma.Inds. do?

Sun Pharmaceutical Industries Ltd is a leading global specialty generic pharmaceutical company, the largest in India, with recent net sales of ₹129,588 Cr and a net profit of ₹21,499 Cr as of March 2025. It has a market cap of ₹414,857 Cr and key metrics include a P/E ratio of 36.00 and a dividend yield of 0.93%.

Overview:<BR>Sun Pharmaceutical Industries Ltd is a large-cap company in the Pharmaceuticals & Biotechnology industry, recognized as the fourth largest global specialty generic company.<BR><BR>History:<BR>Sun Pharmaceutical Industries Ltd was incorporated in 1993 and has since established itself as the largest Indian pharmaceutical company in the US. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 129,588 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 21,499 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 414,857 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.93% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 15.83% <BR>Price to Book: 5.74<BR><BR>Contact Details:<BR>Address: Sun Pharma Advanced Res.Centre, Tandalja Vadodara Gujarat : 390020 <BR>Phone: 91-265-6615500 <BR>Email: secretarial@sunpharma.com <BR>Website: http://www.sunpharma.com

Who are the top shareholders of the Sun Pharma.Inds.?

The top shareholders of Sun Pharma.Inds. include Shanghvi Finance Private Limited (40.3%), institutional investors like mutual funds (12.21%) and FIIs (17.96%), with ICICI Prudential Value Discovery Fund as the largest public shareholder (3.35%), while individual investors hold 5.42%. This indicates strong support from both promoters and institutional investors.

The top shareholders of Sun Pharma.Inds. include a mix of promoters, institutional investors, and individual shareholders. The majority of the shares are held by promoters, with Shanghvi Finance Private Limited being the largest promoter, holding 40.3% of the company. <BR><BR>In terms of institutional holdings, mutual funds account for 12.21% of the shares, with 44 different schemes involved. Foreign Institutional Investors (FIIs) hold 17.96% of the company, represented by 1206 FIIs. The highest public shareholder is ICICI Prudential Value Discovery Fund, which holds 3.35%. Additionally, individual investors collectively hold 5.42% of the shares. <BR><BR>This diverse shareholder structure reflects a strong backing from both promoters and institutional investors.

How big is Sun Pharma.Inds.?

As of 24th July, Sun Pharmaceutical Industries Ltd has a market capitalization of 403,712.00 Cr, with recent net sales of 52,578.44 Cr and net profit of 10,929.04 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Sun Pharmaceutical Industries Ltd has a market capitalization of 403,712.00 Cr, classified as Large Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 52,578.44 Cr, while the sum of Net Profit for the same period is 10,929.04 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025. Shareholder's Funds amount to 72,218.02 Cr, and Total Assets are valued at 87,693.03 Cr.

Are Sun Pharma.Inds. latest results good or bad?

Sun Pharmaceutical's latest results show strong operational performance with a 36.83% increase in net profit and an 8.93% rise in revenue. However, the stock has underperformed, declining 1.46% recently and 8.91% over the past year, leading to a cautious outlook for investors.

Sun Pharmaceutical's latest results present a mixed picture. On one hand, the company demonstrated strong operational performance in Q2 FY26, with net profit reaching ₹3,117.95 crores, reflecting a significant 36.83% increase quarter-on-quarter. Additionally, revenue grew to ₹14,478.31 crores, marking an 8.93% year-on-year increase, and the operating margin improved to 31.43%, indicating effective cost management and operational efficiency.<BR><BR>However, despite these positive financial metrics, the stock has faced challenges in the market. It has declined 1.46% in the latest session and is down 8.91% over the past year, underperforming compared to the Sensex, which gained 3.80% during the same period. The stock is currently trading 12.67% below its 52-week high, which may contribute to cautious investor sentiment.<BR><BR>Overall, while the operational results are strong, the stock's recent performance and market pressures suggest a more cautious outlook. Investors may want to weigh the solid financial results against the stock's underperformance and valuation concerns.

Is Sun Pharma.Inds. technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish due to a bullish MACD and daily moving average, but caution is warranted from mixed signals in longer-term indicators.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the monthly MACD and KST are mildly bearish, indicating some caution. The Bollinger Bands show a mildly bullish trend on the weekly, while the Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. Overall, the strength of the bullish sentiment is tempered by mixed signals in the longer-term indicators.

How has been the historical performance of Sun Pharma.Inds.?

Sun Pharma.Inds. has shown consistent growth from March 2019 to March 2025, with net sales increasing from 29,065.91 Cr to 52,578.44 Cr, and profit after tax rising from 3,209.32 Cr to 10,980.10 Cr. The company has also improved its operating profit margin and cash flow, indicating strong financial health.

Answer:<BR>The historical performance of Sun Pharma.Inds. shows a consistent growth trajectory in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Sun Pharma.Inds. has demonstrated significant growth in net sales, increasing from 29,065.91 Cr in March 2019 to 52,578.44 Cr in March 2025. Total operating income has followed a similar upward trend, reaching 52,578.44 Cr in March 2025, up from 29,065.91 Cr in March 2019. The company's operating profit (PBDIT) has also improved markedly, rising from 7,333.08 Cr in March 2019 to 17,236.73 Cr in March 2025, reflecting a robust operating profit margin of 29.35% in the latest fiscal year. Profit before tax has surged to 13,752.13 Cr in March 2025, compared to 3,810.20 Cr in March 2019, while profit after tax reached 10,980.10 Cr, up from 3,209.32 Cr in March 2019. The company's total assets have increased from 65,077.17 Cr in March 2020 to 87,693.03 Cr in March 2025, indicating strong asset growth. Total liabilities have also risen, from 65,077.17 Cr in March 2020 to 87,693.03 Cr in March 2025, with total debt decreasing from 7,578.30 Cr in March 2020 to 1,869.63 Cr in March 2025. Cash flow from operating activities has improved significantly, reaching 14,072.00 Cr in March 2025, compared to 6,554.00 Cr in March 2020, contributing to a closing cash and cash equivalent of 10,268.00 Cr in March 2025. Overall, Sun Pharma.Inds. has shown a strong upward trend in revenue, profitability, and cash flow, positioning itself favorably in the market.

Should I buy, sell or hold Sun Pharma.Inds.?

Which are the latest news on Sun Pharma.Inds.?

Why is Sun Pharma.Inds. falling/rising?

As of 04-Dec, Sun Pharmaceutical Industries Ltd's stock price is rising, currently at 1,818.60, due to strong performance metrics and positive investor sentiment. The company shows robust fundamentals, including significant growth rates and substantial institutional backing, despite some valuation concerns.

As of 04-Dec, Sun Pharmaceutical Industries Ltd is experiencing a rise in its stock price, currently at 1,818.60, with an increase of 12.9 (0.71%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.42% today and has shown consecutive gains over the last two days, with a total return of 1.14% during this period. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Moreover, the company demonstrates strong long-term fundamentals, including a healthy annual growth rate in net sales of 11.10% and an operating profit growth of 21.96%. With a low debt-to-equity ratio and a return on equity of 15.21%, Sun Pharma is positioned favorably in terms of profitability. The positive financial results reported on September 25, including the highest operating cash flow and cash equivalents, further bolster investor confidence.<BR><BR>Institutional holdings are also significant at 36.79%, suggesting that knowledgeable investors are backing the stock, which can positively influence its price. Despite some concerns regarding its valuation, as indicated by a high price-to-book value ratio and a relatively low profit growth compared to stock returns, the overall sentiment remains positive, contributing to the stock's rise.